DEFA14A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 12, 2021

Aditxt, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-39336	82-3204328
(State or other jurisdiction of incorporation)	(Commission File Number)	(IRS Employer Identification No.)

737 N. Fifth Street, Suite 200 Richmond, VA	23219
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (650) 870-1200

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☒ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001	ADTX	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

Item 7.01 Regulation FD Disclosure

Attached as Exhibit 99.1 to this Current Report on Form 8-K is an updated version of Aditxt, Inc.’s (the “Company”) investor presentation, which may be used in presentations to investors from time to time.

The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K is furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report, regardless of any general incorporation language in any such filing.

Additional Information and Where to Find It

This communication may be deemed to be solicitation material in respect of the proposed transaction with AiPharma Global Holdings LLC (“AiPharma Global”). If the definitive agreement is entered into with AiPharma Global, it is contemplated by the Transaction Agreement that, a Proxy Statement / Registration Statement on Form S-4 (the “Registration Statement”) will be filed with the Securities and Exchange Commission (the “SEC”), which will include preliminary and definitive proxy statements to be distributed to the Company’s shareholders in connection with the Company’s solicitation for proxies for the vote by the Company’s shareholders in connection with the proposed transaction  and other matters specified in the Proxy Statement / Registration Statement, as well as the prospectus relating to the offer of securities to be issued to AiPharma Global’s shareholders in connection with the completion of the proposed transaction.  After the Proxy Statement / Registration Statement has been filed and declared effective, the Company will mail a definitive proxy statement and other relevant documents to its shareholders as of the record date established for voting on the proposed business combination.  WE URGE INVESTORS TO READ THESE MATERIALS CAREFULLY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE DEFINITIVE AGREEMENT.  Investors will be able to obtain free copies of these materials on the SEC’s website at http://www.sec.gov.  Free copies of the Company’s SEC filings are also available from Aditxt, Inc., 737 N. Fifth Street, Suite 200, Richmond, VA 23219, Attn: Amro Albanna, Chief Executive Officer.

Participants in the Solicitation

The Company and its executive officers, directors, other members of management, employees and AiPharma Global may be deemed, under SEC rules, to be participants in the solicitation of proxies from the Company’s shareholders with respect to the proposed transaction.  Information regarding the executive officers and directors of the Company is set forth in its definitive proxy statement for its 2021 annual meeting filed with the SEC on April 5, 2021.  More detailed information regarding the identity of potential participants, and their direct or indirect interests, by securities holdings or otherwise, will be set forth in the Proxy Statement / Registration Statement on Form S-4 and other materials to be filed with the SEC in connection with the Definitive Agreement.

INVESTMENT IN ANY SECURITIES DESCRIBED HEREIN HAS NOT BEEN APPROVED OR DISAPPROVED BY THE SEC OR ANY OTHER REGULATORY AUTHORITY NOR HAS ANY AUTHORITY PASSED UPON OR ENDORSED THE MERITS OF THE OFFERING OR THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED HEREIN. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE. 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description
99.1	Investor Presentation
104	Inline XBRL for the cover page of this Current Report on Form 8-K

-1-

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ADITXT, INC.
Date: October 12, 2021	By:	/s/ Corinne Pankovcin
		Corinne Pankovcin
		President

-2-

EX-99.1

Exhibit 99.1

Innovation in monitoring and treatment of the immune system

Safe Harbor Statement This presentation contains forward - looking statements that are subject to many risk and uncertainties. Forward - looking statement s include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other thi ngs, our ongoing and planned product development; our intellectual property position; our ability to develop commercial functions; expectation s r egarding project launch and revenue; our results of operations, cash needs, spending, financial condition, liquidity, prospects, growth and st rat egies; the industry in which we operate; and the trends that may affect the industry or us. Although we believe we have a reasonable basis for ea ch statement, we caution you that forward looking statements are not guarantees of future performance. Actual results may differ materially from those indicated by these forward - looking statements as a result of various important those risks more fully discussed in the section entitled “Risk Factors” in the Company’s prospectus, dated June 29, 2020, tha t U.S. Securities and Exchange Commission under File No. 333 - 235933, as well as discussions of potential risk, uncertainties, and factors in the Company’s subsequent filings with the U.S. Securities and Exchange Commission. All such statements speak only made, and the Company undertakes no obligation to update or revise publicly any forward - looking statements, whether as a information, future events or otherwise. 2 ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

3 Agenda Company Immune Monitoring Immune Treatment ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

4 2020 Thrust the Immune System into a Whole New Focus ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

5 HighTech BioTech Approach to Immune Health Aditxt is innovating and commercializing technologies focused on monitoring and treatment of the immune system ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system Immune Monitoring & Treatment Biologics Bioinformatics Data & A.I. Manufacturing Diagnostics

Allergy COVID - 19 Influenza Celiac Disease Type 1 Diabetes Islet Cell Transplantation Psoriasis Atopic Dermatitis Vitiligo Alopecia Organ Transplant Skin Allograft Transplantation Multiple Sclerosis 6 Potential Markets* Autoimmune Disease Infectious Diseases Allergy Organ & Tissue Transplant Central Nervous System Dermatology $100 B $99 B $25 B $8.4 B $116 B $37 B ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system *Refer to slide 32 for market size sources

7 Strategically Located Silicon Valley, CA Richmond, VA CLIA - certified AditxtScore Ρ operation Hub of capital markets, investor and media relations, and business development Hub of discovery and product development New York City, NY Berlin, Germany Autoimmunity clinical work ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

A team to deliver 8 Amro Albanna Co - founder & CEO Corinne Pankovcin President Thomas J. Farley, CPA Chief Financial Officer Rowena Albanna Chief Operating Officer Jennifer Lee Director of Human Resources Shahrokh Shabahang, MS, PhD РCo - founder, Chief Innovation Officer, Board Member Joseph P. McConnell, PhD, DABCC, FAACC Senior Vice President of Laboratory Science Dolly Tyan, PhD, D(ABHI) - SVP Clinical Development, Transplantation Daniel Heofner , MT, PhD, DABCC, FAACC Director of Laboratories Joachim - Friedrich Kapp, MD, PhD - SVP Clinical Development, Autoimmunity Anastasia Katany, D.O. ABFM, FAARFM, ABAARM VP of Products, AditxtScore ΠAnthony Voorhies Head of Business Development, AditxtScore ΠADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

Independent Board Members 9 Our independent board members are comprised of the government and industry’s leading experts with backgrounds ranging from finance to medicine. LAURA ANTHONY Director & Chair of Nominating & Corporate Governance Committee Securities attorney providing corporate counsel to small - cap and middle market private and public companies. Focus includes compliance with the Securities Act of 1933 offer sale and registration requirements, including private and public offerings; IPOs; compliance with the NASDAQ and NYSE American initial and continued listing requirements; compliance with the registration and reporting requirements under the Securities Exchange Act of 1934; and mergers and acquisitions. LAUREN CHUNG, Ph.D. Director Venture partner at Yozma Group Korea. Founder and CEO of MINLEIGH LLC. Former managing director in Healthcare Research at WestPark Capital and co - founder of Tokum Capital Management, a global healthcare fund, which merged with Perella Weinberg Partners. Previously managed healthcare investment portfolios at institutional investment firms. Served as a research scientist doing cutting - edge work in neurodegenerative and genetic disorders at Massachusetts General Hospital/Harvard Medical School and Boston Children’s Hospital. JEFFREY RUNGE, MD, FACEP Director Former Chief Medical Officer & Assistant Secretary for Health Affairs of the U.S. Department of Homeland Security. Has over 35 years of experience as a physician, board certified in emergency medicine, with two decades of experience as a Federal government and healthcare executive. Has expertise across the fields of homeland defense, threat mitigation and prevention, medical preparedness, and medical services delivery. Also served as the head of two federal agencies (2001 - 2008). NAMVAR KIAIE Director & Chair of Compensation Committee Senior R&D leader and Head of R&D for the New Analyte Ventures at Abbott Diabetes Care, managing up to 80 R&D Engineers and Scientists in developing Abbott’s next generation biosensing technologies. Responsible for the successful development of 40+ novel diabetes management related products, including FreeStyle Libre. BRIAN BRADY, CFA, MBA Director & Chair of Audit Committee Former Senior Portfolio Manager/VP at Northern Trust who led the investment practice in the Fort Worth and West Texas marketplace. Extensive experience with financial markets and investment due diligence. Currently serves as Director of Investments for a large hospital system. ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

10 Innovation in partnership with research institutions Global Network of Collaborators Commercialization with market access partners Business infrastructure ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

Immune Monitoring 11 ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

12 • Each person’s immune system is unique and responds differently to viruses, bacterial antigens, peptides, drugs, bone marrow and solid organ transplants, and cancer • By measuring and monitoring each individual’s unique immune system, Aditxt delivers an unparalleled approach to both monitoring and treating immune health with precision The need for understanding our immune system in order to practice precision medicine ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

13 AditxtScore ۲ Cellular Immunity Assessment Can detect 100 different targets Four - hour assay Sensitivity = 1 / 106 cells Evaluation of memory B cell response (v. 2.0) Chen G, Liu H, Tyan D. FlowSpot: Real time prediction and monitoring of cellular immune profiles for responses to pathogens, vaccines, therapeutics, and transplantation. Manuscript submitted for publication. ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system • AditxtScore is a proprietary platform that provides a personalized, comprehensive profile of a patient’s individual immune system • Can be useful in anticipating attacks on the body • Initial technology was licensed from, invented and used at Stanford University • AditxtScore technologies are protected by 2 patent families • Substantial know - how and trade secrets in development and commercialization An Innovative Way to Map the Whole Immune System

14 How it Works Patient Provides Samples Samples are processed at the AditxtScore ۲ Center confidentially AditxtScores ۲ of the Immune system are generated 1. 2. 3. ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

15 ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

16 Detection of auto - antibodies to all 4 beta cell antigens in a single multiplex assay Monitoring of disease progression Monitoring of response to therapy AditxtScore Ρ for T1D AditxtScore ۲ for Type - 1 Diabetes: Early Detection of Auto - antibodies ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

BRAIN THYROID CARDIO - METABOLIC GUT HEALTH DIABETES BONES AND JOINTS HORMONE IMBALANCES 17 Future Applications Future Applications ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

18 Scaling Up for Millions of Tests High - capacity, CLIA - certified AditxtScore ۲ immune monitoring center in Richmond, Virginia Introduced in a joint press conference including Virginia Governor Ralph Northam and Richmond Mayor Levar Stoney Scaling to process up to 10 million AditxtScores TM annually ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

Immune Treatment 19 ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

20 Therapeutic Platforms Immune Modulation RNAi ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

21 Disclaimers about Transaction Agreement To Acquire AiPharma , Rights Holder Of Antiviral Tablet Avigan / Reeqonus / Qifenda Used in the Treatment of Over 1.5 Million Covid - 19 Patients Outside the U.S. and Canada, (information filed on Aditxt , Inc.’s Form 8 - K dated October 4, 2021) ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system Disclaimers: The information contained in this Presentation regarding AiPharma is derived solely from management of AiPharma and otherwise publicly available information and does not purport to be all - inclusive. The information has not been independently verified. The acquisition is subject to the satisfaction of numerous conditions, including satisfactory due diligence, the negotiation and execution of definitive agreements and other closing conditions, including board and shareholder approval and approval by Nasdaq of the listing of shares proposed to be issued in the transaction. The partie s h ave entered into a transaction agreement to reach a definitive agreement by the end of November 2021. However, there can be no assurance that a definitive agreement will be entered into or that the propose d a cquisition will be completed as proposed or at all. This Presentation includes certain projections and forward - looking statements provided by the Company, including with respect to the anticipated future performance of the Company, a potential business combination transaction with AiPharma and our ability to develop and commercialize products and obtain regulatory approvals. Such projections and forward - looking st atements reflect various assumptions of management, and are subject to significant business, regulatory, economic and competitive uncertainties and contingencies, m any of which are beyond the control of the Company. Accordingly, there can be no assurance that such projections or forward - looking statements will be realized. Actual results may vary from anticipated res ults and such variations may be material. Therefore, you should not rely on any of these projections or forward - looking statements. Important factors that could cause our actual results to differ materially from those indicated in the projections or forward - looking statements include, among others: (i) statements regarding the therapeutic potential of AiPharma’s products are based on preclinical and clinical findings and observations and actual trial results may differ; (ii) the clinic al and commercial risks associated with our products and those of AiPharma remain high and failure can unexpectedly occur at any time prior to regulatory approval; (iii) the risk that AiPharma’s preclinical or clinical studies may be delayed or fail to be completed on time or not at all; (iv) risks associated with the regulatory approval process; (v) our or AiPharma’s ability to enter strategic relationships for development or commercialization of our respective products; (vi) patents may not issue from our patent applications, patents that have issued may not be enf orc eable, or additional intellectual property licenses from third parties may be required; (vii) our ability to obtain sufficient financing; and (viii) our ability to consummate on terms that are favorable to us or at all any potential strategic transactions, including the proposed business combination transaction with AiPharma . Any projection or forward - looking statement made by us in this Presentation is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to update any projection or forward - looking statement, whether written or oral, th at may be made from time to time, whether as a result of new information, future developments or otherwise. On October 4, 2021, Aditxt, Inc. (the “Company”) entered into a transaction agreement (the “Transaction Agreement”) with AiPharma Global Holdings LLC (“ AiPharma Global”), pursuant to which the Company agreed to reach a definitive agreement (the “Definitive Agreement”) no later than November 30, 2021 to acquire a subsidiary ( “ AiPharma Subsidiary” or “Holdco”) of AiPharma Global, which is to own all of the assets of AiPharma Global following a restructuring of AiPharma Global, subject to certain termination rights described below. The Company previously announced that it had entered into a le tt er of intent to acquire a target company (the “Letter of Intent”), which was reported in the Company’s Current Report on Form 8 - K dated August 2 5, 2021.

22 Key Metrics About AiPharma and its Brands ( Avigan /Reeqonus/ Qifenda )* • AiPharma is rights holder of antiviral tablet Avigan/Reeqonus/Qifenda used in the treatment of over 1.5 million COVID - 19 patients outside the U.S. and Canada • Avigan has full marketing authorization or emergency use authorization as a treatment for COVID - 19 in Mexico, India, Indonesia, Thailand and Malaysia, with many other countries buying the drug under compassionate use programs including the United Kingdom, United Arab Emirates, Greece, Hungary and Saudi Arabia • AiPharma Global generates revenues from worldwide sales outside the U.S. and Canada of Avigan/Reeqonus through its 50% equity stake in Global Response Aid ("GRA”) • GRA is part of a consortium that includes Appili Therapeutics (TSX: APLI; OTCQX: APLIF), Dr. Reddy’s Laboratories (NYSE:RDY), Agility (KSE/DFM: AGLTY) and FUJIFILM Toyama Chemical Co. Ltd, a subsidiary of FUJIFILM Holdings (FUJIY); Consortium members work together to coordinate and accelerate the worldwide development of Avigan/Reeqonus ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system The acquisition of AiPharma is subject to the satisfaction of numerous conditions, including satisfactory due diligence, the negotiation and execution of d efinitive agreements and other closing conditions. AVIGAN/REEQONUS is a highly effective oral anti - viral that is administered at home, early in the course of infection, preventing transmission of the virus and hospitalization, ultimately saving lives. AVIGAN/REEQONUS is uniquely positioned to address the current COVID - 19 pandemic and future viral outbreaks now, outbreaks now, and into the future. *The 200mg dosage is marketed under the brand name AVIGAN, and in North America, REEQONUS.

23 Phase 3 U.S. Study Being Conducted by AiPharma’s Consortium Partner Appili Therapeutics Topline results expected in <60 days planned acquisition of AiPharma • Phase 3 PRESECO (PREventing SEvere COVID - 19) trial evaluating oral Avigan®/Reeqonus ۲ (favipiravir) as a potential COVID - 19 treatment conducted by consortium partner • Enrollment of 1,231 COVID - 19 patient patients enrolled with mild - to - moderate disease including with Delta variant • Goal is for Avigan/Reeqonus to become standard of care in the US for mild - to - moderate COVID - 19 patients to resolve symptoms rapi dly at home AiPharma recently agreed to acquire a major stake in Appili Therapeutics • AiPharma expects to own 19.4% of the issued and outstanding Appili shares following the closing of its transaction expected Q 4 2 021 ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system The acquisition of AiPharma is subject to the satisfaction of numerous conditions, including satisfactory due diligence, the negotiation and execution of d efinitive agreements and other closing conditions.

24 ENCODES TARGET PROTEIN ENCODES PRO - APOPTOTIC PROTEIN AditxtReprogramming ۲ Platform to Modulate the Immune System Plasmid DNA inducing tolerance - inducing target protein Plasmid DNA inducing natural ‘programmed’ cell death Immune reprogramming (immune tolerance) therapies reprogram the immune system so that disease - causing immune responses are stopped while maintaining the immune system’s ability to combat pathogenic infection. AditxtReprogramming technologies are protected by 7 patent families AditxtReprogramming ۲ ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

25 IP Portfolio AditxtReprogramming ۲ technologies are protected by 7 patent families, including: • 8 U.S. patents, 4 U.S. pending patent applications, 86 foreign patents, and 14 foreign pending patent applications (EU, Austr ali a, Canada, Japan, China, India, Hong Kong) AditxtReprogramming ۲ patents are broadly categorized into 3 groups: • Autoimmune diseases and type 1 diabetes • Organ transplantation and a method of producing plasmid DNA that is mammalian - like to prevent immune activation • Composition of matter for a tolerance delivery system for antigens of interest (basis for a platform allowing development of a n ew class of immunotherapeutics for various indications) The projected expiration dates for the ADi ۲ patents range from 2021 to 2032. We also possess and/or in - license substantial know - how and trade secrets relating to the development and commercialization of ou r product candidates, including related manufacturing processes and technologies. ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

26 Preclinical Proof of Concept with ADi ۲ Skin Allograft Transplantation Type 1 Diabetes (Autoimmunity) Alopecia Areata (Autoimmunity) Psoriasis (Autoimmunity) 21 Days 58 Days Immunosuppression alone Allograft lost in 21 days on average ADi Œ with minimal immunosuppression 3 - fold increase in the longevity of the skin allografts 10 15 20 25 30 35 40 0 100 200 300 400 500 600 ADi Tx of NOD mice at >200 mg/dL Age (weeks) F a s t i n g B l o o d G l u c o s e ( m g / d L ) 1 2 3 4 5 6 7 8 9 10 11 12 Administration of ADi TM using GAD as the antigen over an 8 - week period in animals with T1D restores insulin production and reverses hyperglycemia ADi TM protects hair follicles from autoimmune attack Methylated vector Unmethylated BAX Methylated BAX 0 0,1 0,2 0,3 Psoriasis Induced - ADi Treated Psoriasis Induced - Untreated Increase in Skin Thickness Change in thickness (mm) 0 0,5 1 1,5 Psoriasis Induced - ADi Treated Psoriasis Induced - Untreated Increase in Scaling Scaling Score (range = 0 - 4) ADi TM treatment resulted in a 69% reduction in skin thickening and 38% reduction in scaling over the 10 - day study period* in an established psoriasis model ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

27 AditxtReprogramming ۲ Clinical Pipeline ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

28 Deal Date Licensor Licensee Phase of Development Indication(s) Deal Type Upfront Payment (M) Milestone Payment (M) Total Deal Value (M) 13 - Nov - 2019 Exicure Allergan Discovery Alopecia License - Collaboration (option) $25 $725 $770 30 - Oct - 2019 Pandion Therapeutics Astellas Pharma Discovery Type 1 Diabetes License - Collaboration $45 $750 $795 29 - Oct - 2018 Denali Therapeutics Sanofi Genzyme Phase 1 Clinical Psoriasis and other CNS indications License - Collaboration (option) $125 $1,095 $1,220 02 - Dec - 2016 Exicure Purdue Pharma Phase 1 Clinical Psoriasis License - Collaboration (option) $10 $777 $787 02 - Jun - 2015 Anokion Astellas Pharma Discovery Type 1 Diabetes and Celiac disease License - Collaboration Undisclosed Undisclosed $760 Significant Value in a Partner - Centric Approach Notable Recent Licensing Transactions Significant opportunity in pharma backed indications Significant upside potential in low saturated indication Source: Cortellis Health Intelligence ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

29 Equity Profile Ticker ADTX Market Cap (as of 10/11/21) ~$36.1 M Share Price (as of 10/11/21) $1.78 Shares Outstanding (as of 8/31/21) ~20.3 M Avg. Daily Trading Volume (90 day) (as of 10/11/21) 5.6 M Cash on Hand (6/30/21) $8.6 M ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

30 • https:// www.alliedmarketresearch.com /autoimmune - disease - therapeutics - market • https:// www.bchttps :// www.alliedmarketresearch.com /allergy - treatment - market#:~:text=The%20global%20allergy%20treatment%20market,6.3%25%20from%202018%20to%202025.cresearch.com/market - research/pharma ceuticals/infectious - disease - treatments - markets - report.html #:~:text=The%20global%20market%20for%20infectious,8.9%25%20from%202017%20to%202022 • https:// www.alliedmarketresearch.com /allergy - treatment - market#:~:text=The%20global%20allergy%20treatment%20market,6.3%25%20from%202018%20to%202025 • https:// www.grandviewresearch.com /industry - analysis/transplantation - market • https:// www.grandviewresearch.com /industry - analysis/central - nervous - system - cns - therapeutic - market#:~:text=The%20global%20CNS%20therapeutic%20market,USD%20124.0%20billion%20in%202021 • https:// www.fortunebusinessinsights.com /dermatology - drugs - market - 104432 Appendix: sources ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system

Aditxt Inc. (Aditxt ۲ ) 737 N. Fifth Street, Suite 200 Richmond, VA 23219 Direct: 650 - 870 - 1440 | Main: 650 - 870 - 1200 Ext. 440 31 ADTX | A ditxt.com | Innovation in monitoring and treatment of the immune system